Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2026 | DOVACC: olaparib, durvalumab, and UV1 vaccine in BRCA-wildtype ovarian cancer

Trine Nøttrup, PhD, Rigshospitalet, Copenhagen, Denmark, discusses first results from the randomized Phase II ENGOT-OV56/NSGO-CTU-DOVACC (NCT05116189) trial evaluating olaparib maintenance alone, with durvalumab, or with durvalumab plus the telomerase-targeting UV1 vaccine in patients with BRCA-wildtype recurrent ovarian cancer. The triplet showed a numerical progression-free survival improvement over olaparib alone that did not reach statistical significance, with an exploratory restricted mean survival time analysis favoring the triplet regimen. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

This trial, brief called DOVACC, was initiated by the NSGO CTU and our former medical director Mansour Mirza. And in the trial, we tried to evaluate if the addition of the UV1 vaccine to a maintenance treatment of Olaparib and Durvalumab could increase the progression-free survival for patients with recurrent ovarian cancer. The patients have to have had platinum-based treatment and no more than three further lines...

This trial, brief called DOVACC, was initiated by the NSGO CTU and our former medical director Mansour Mirza. And in the trial, we tried to evaluate if the addition of the UV1 vaccine to a maintenance treatment of Olaparib and Durvalumab could increase the progression-free survival for patients with recurrent ovarian cancer. The patients have to have had platinum-based treatment and no more than three further lines. And the best results of the last line had to be stable disease or non-progressive disease. Then we randomized the patient one to one to two, one group receiving Olaparib, that was Arm A, Arm B receiving Olaparib and Durvalumab, and Arm C receiving Olaparib, Durvalumab, and then the experimental vaccine. And they had eight vaccines within the first few months of the trial. We saw the results of the study with their survival benefit towards the group who had the vaccine of 8.7 months compared to the Arm-A, which was our primary endpoint, the progression-free survival, Arm-C versus Arm-A. And the PFS in Arm-A was 5.9 months. Unfortunately, these results did not reach statistical significance. So we cannot say that adding the vaccine was proven to be a longer PFS, but it definitely showed that some patients do benefit from it. If we do look into the subgroups, we see that especially the subgroup of HRD patients and the subgroup of patients who had had no prior PARP could gain from adding the vaccine to a maintenance therapy. When we looked at our secondary endpoint, comparing Arm C to Arm B, comparing adding the vaccine to a combination of Durvalumab and Olaparib, unfortunately, we didn’t see any results that were statistically significant. So these are the prime efficacy endpoints. When we come to toxicity, really adding the vaccine to Olaparib and Durvalumab only added a few vaccine-related side effects like headache, flu, and some itching and redness where they had the vaccine. But of course adding Durvalumab to Olaparib added some more toxicity to the patients. But everything was manageable and we saw no grade 5 events. Generally the combination was well tolerated.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.